NOT-gated chimeric antigen receptor circuits in T and NK cells

Area of Science:

• Immunology
• Oncology
• Cell Therapy

Background:

• Chimeric antigen receptor (CAR) T cells are effective cancer immunotherapies.
• Limited tumor-specific antigens restrict the therapeutic window for most cancers.
• NOT-gated CAR circuits offer a solution by combining activating (aCAR) and inhibitory (iCAR) components for dual antigen targeting.

Purpose of the Study:

• To systematically evaluate NOT-gated CAR circuits for improved cancer immunotherapy.
• To investigate the impact of different CD3ζ signaling domains on aCAR function.
• To assess the potential of NOT-gated CAR circuits in T cells and natural killer (NK) cells.

Main Methods:

• Systematic evaluation of over 60 pairs of NOT-gated CAR circuits.
• Analysis of inhibitory dose-response characteristics based on CD3ζ signaling.
• Assessment of T cell exhaustion phenotypes in LIR1-iCAR-expressing cells.
• Mechanistic studies to identify intracellular regulators (e.g., SHP-1).
• Functional transfer of NOT-gated circuits into primary NK cells.

Main Results:

• Diverse inhibitory dose-response profiles were observed, influenced by the aCAR's CD3ζ domain.
• T cells expressing LIR1-iCAR exhibited reduced exhaustion phenotypes.
• SHP-1 was identified as a key regulator of LIR1-iCAR and cis-iCAR function.
• NOT-gated CAR circuits were successfully transferred and functional in NK cells.

Conclusions:

• NOT-gated CAR circuits provide a versatile platform for precise tumor targeting in cancer immunotherapy.
• This strategy enhances safety and efficacy by overcoming single-antigen limitations.
• The developed circuits hold promise for next-generation T cell and NK cell-based therapies.